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Introduction
Strongyloidiasis is a disease caused by an infection with a soil-transmitted helminth that affects,
according to largely varying estimates, between 30 million and 370 million people worldwide
[1,2]. Not officially listed as a neglected tropical disease (NTD), strongyloidiasis stands out as
particularly overlooked [3]. Indeed, there is a paucity of research and public health efforts per-
taining to strongyloidiasis. Hence, clinical, diagnostic, epidemiologic, treatment, and control
aspects are not adequately addressed to allow for an effective management of the disease, both
in clinical medicine and in public health programs [4]. The manifold signs and symptoms
caused by Strongyloides stercoralis infection, coupled with the helminth’s unique potential to
cause lifelong, persistent infection, make strongyloidiasis relevant beyond tropical and subtrop-
ical geographic regions, where, however, most of the disease burden is concentrated. Indeed,
strongyloidiasis is acquired through contact with contaminated soil, and the infection is, thus,
primarily transmitted in areas with poor sanitation, inadequate access to clean water, and lack
of hygiene.
While the actual morbidity of chronically infected, immunocompetent individuals is subtle
and difficult to appreciate [5], the particular importance of this parasitic worm is linked to its
potential for maintaining lifelong autoinfections and causing a life-threatening hyperinfection
syndrome in immunocompromised individuals [6]. Lack of point-of-care (POC) diagnostics
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and poor availability of, and access to, ivermectin (the current treatment of choice) are the two
most significant bottlenecks that hinder effective management of the disease both in clinical
and in public health settings. Examples of the management and importance of strongyloidiasis
in two clinical contexts (in a tropical setting and a high-income country) and from a public
health perspective are given in Boxes 1–3.
In 2011, a web-based platform became operational with the aims of sharing information
and supporting research collaborations on S. stercoralis (Strongyloides Sharing Platform; see
http://ezcollab.who.int/ntd/strongyloidiasis). This platform was initiated by the Department of
Control of Neglected Tropical Diseases, World Health Organization (WHO), with the support
of the WHO Collaborating Centre on Strongyloidiasis in Negrar (Verona, Italy). The main
research needs and areas of interest of the Strongyloides Sharing Platform are summarized in a
Viewpoint published in PLoS Neglected Tropical Diseases in 2013 [1]. Three main areas of
research were highlighted: (i) assessment of the prevalence and disease burden of strongyloidi-
asis in different epidemiologic settings; (ii) development of novel diagnostic methods, such as
screening of patients at highest risk and clinical management approaches; and (iii) enhancing
the availability of, and access to, ivermectin, including research and development of alternative
drugs and treatment regimens.
In September 2015, some 40 scientists and public health experts—including representatives
of leading institutes of tropical medicine, WHO, and WHO Collaborating Centers—met dur-
ing the 9th European Congress on Tropical Medicine and International Health (ECTMIH) in
Basel, Switzerland. The main objectives of the meeting were (i) to discuss recent progress with
an emphasis on diagnostics and treatment of S. stercoralis, particularly since the establishment
of the Strongyloides Sharing Platform; (ii) to provide an update on the global status of strongy-
loidiasis, particularly regarding the integration of S. stercoralis into the WHO’s preventive che-
motherapy control strategy for soil-transmitted helminthiasis, and the steps required to
achieve access to ivermectin treatment in endemic countries; and (iii) to outline a Strongy-
loides-related research agenda for the years to come. Moreover, the meeting provided an
opportunity to launch a new research network–StrongNet. Of note, StrongNet is based on the
existing Strongyloides Sharing Platform but has a more inclusive scope. It is thus open to any
interested researcher and institution in order to foster collaborations and deepen exchange
Box 1. Individual Living in an Endemic Area with Diarrhea,
Abdominal Pain, Pruritus, and Significant Dermatological
Manifestations [10]
A 43-year-old male farmer, living in the rural eastern part of Preah Vihear province,
northern Cambodia, was diagnosed with a heavy Strongyloides stercoralis infection (924
and 478 larvae present in two Baermann examinations). Additionally, larvae and adult S.
stercoralis were detected in Koga agar plate culture examinations of the stools. The
patient was co-infected with hookworm and presented with abdominal pain, diarrhea,
nausea, vomiting, fever, and a pronounced and persistent skin rash, which had been pres-
ent with extensive itching for more than two years. The rash was observed on the back,
chest, abdomen, and extremities and, due to frequent and intense scratching, showed
signs of focal infection. Three weeks after treatment with a single oral dose of ivermectin
(200 μg/kg) and a single oral dose of mebendazole, the patient’s rash had almost disap-
peared, and he was free of episodes of intensive itching.
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(e.g., establishment and exchange of stool and serum banks for Strongyloides research, multi-
center drug and diagnostic studies, linking up researchers, public health experts, and connect-
ing existing networks with related and overlapping interests).
During the meeting, the discussion addressed three main areas: (i) epidemiology and diag-
nosis of S. stercoralis infections; (ii) treatment options and global access to ivermectin; and (iii)
public health strategies for the control of strongyloidiasis in endemic countries. Here, we
review and summarize recent developments, describe the priorities identified during the Sep-
tember 2015 meeting, and outline specific recommendations and challenges for future research
and public health interventions.
Diagnosis of Strongyloidiasis
Current Diagnostic Armamentarium and New Developments
Most S. stercoralis infections are chronic with an intermittent and low larval output. Hence,
parasitologic methods, which visualize the presence of S. stercoralis larvae in stool, have only
modest sensitivity [7–9], although the diagnosis is easy in heavy infections that are often found
in highly endemic areas, as illustrated by the example in Box 1.
The Baermann funnel technique and the nutrient agar plate cultures (e.g., Koga agar plate)
show reasonable sensitivity [11] with comparable diagnostic accuracy [12]. However, repeated
stool sampling and a combination of both methods are recommended to achieve high sensitiv-
ity [10,13]. Importantly, though, the Baermann and Koga agar plate techniques are poorly stan-
dardized, which renders inter-laboratory comparisons difficult.
Peripheral blood eosinophilia is a useful, yet an unspecific, marker for infection with S. ster-
coralis in non-endemic areas (Box 2). Nonetheless, raised eosinophil counts may be absent,
particularly (but not exclusively) in patients with a severe hyperinfection syndrome.
Because of their excellent sensitivity, serologic assays remain the mainstay of S. stercoralis
screening, particularly in high-income countries, where serology can also be used to monitor
Box 2. In-Depth Diagnostic Assessment of Eosinophilia in High-
Income Countries
A 42-year-old, otherwise asymptomatic female patient from Croatia presented to a Ger-
man hospital because of persistent peripheral blood eosinophilia of15% and elevated
IgE antibody titers. After an in-depth diagnostic assessment for hematologic and autoim-
mune disorders, several stool samples were analyzed for the presence of intestinal para-
sites. The formalin-ether concentration technique and the Baermann funnel technique
were used, but neither helminth eggs nor intestinal protozoa cysts were identified. How-
ever, a serologic examination showed the presence of high anti-Strongyloides antibody
titers. The patient was thus treated with oral ivermectin (200 μg/kg) for two days. After
one week, the eosinophil counts were in the normal range, and repeated serology after
three months showed a significant decrease of the anti-Strongyloides antibody titers. The
patient had lived in Germany for more than a decade, but reported regular travels to
rural Croatia. Even though Croatia is not considered to be an endemic country for
human strongyloidiasis, this does not exclude that the patient acquired an infection with
S. stercoralis there, as epidemiologic data from southeast Europe are scant and endemic
areas may have remained undetected.
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treatment success. Antibody titers usually demonstrate sero-reversion or significantly decrease
within months after successful treatment [14]. Moreover, serology lends itself to prevalence
surveys in low- and middle-income countries (LMIC). It must be noted, though, that serology
might give false-negative results in immunocompromised individuals and in recently acquired
infections [15,16]. False-positive results are also possible in individuals with other parasitic
infections; therefore, serologic testing must be interpreted with caution in areas where strongy-
loidiasis is endemic [17]. In a comparative assessment of serologic methods, two commercial
and three in-house serologic tests showed reasonable sensitivity and a very high specificity over
a given cutoff. Of note, a luciferase immunoprecipitation system-based assay (LIPS) that
employs a recombinant antigen (NIE) was found to be the most specific method, but this assay
is not widely available [9,18].
The Leiden University Medical Center (LUMC; Leiden, the Netherlands) developed and
implemented a highly standardized multiplex real-time polymerase chain reaction (PCR) assay
for a range of helminths, including S. stercoralis [19,20]. The technique showed high sensitivity
according to a large number of samples subjected to this platform between 2006 and 2012,
comprising patient samples from the Netherlands and several African, Asian, and South Amer-
ican countries.
Recent comparative studies performed in different settings evaluated conventional diagnos-
tic methods and molecular tools for the detection of S. stercoralis in human stool samples and
showed that quantitative real-time PCR is the most sensitive single stool-based diagnostic
Box 3. Impact of Preventive Chemotherapy with Ivermectin and
Albendazole on the Prevalence of S. stercoralis and Other
Infectious Agents [46,48,49]
The Global Program to Eliminate Lymphatic Filariasis (GPELF) instituted annual
administration of ivermectin and albendazole in Zanzibar (Pemba and Unguja Islands)
from 2001 to 2006. After six rounds of community-based treatment with a coverage of
more than 80%, lymphatic filariasis (LF) microfilaremia and antigen levels in sentinel
and spot-check sites were below the thresholds of sustaining transmission, though a sub-
sequent transmission assessment survey indicated that LF was not yet completely elimi-
nated, especially from Pemba. Data from surveys prior to the GPELF showed
prevalences of S. stercoralis of about 41% and 35% on Pemba and Unguja, respectively.
After the termination of the GPELF intervention, the prevalence of S. stercoralis dropped
on both islands to 7%. Despite the extremely high transmission of other helminths (i.e.,
Ascaris lumbricoides, Trichuris trichiura, and hookworm), a 90% decline in the health
clinics records was shown. Moreover, scabies had been rampant on both islands, but the
number of scabies cases that were reported from health services dramatically declined
(by 68%–98%) in the years following the periodic treatment with ivermectin. Addition-
ally, the combination of ivermectin with albendazole (or mebendazole) showed a higher
efficacy than benzimidazole monotherapy against soil-transmitted helminth infections,
particularly for T. trichiura. Ivermectin may have also contributed to the success of an
ongoing malaria control intervention; indeed, malaria is now on the verge of elimination
in Zanzibar, and it has been hypothesized that ivermectin-containing blood meals might
have had an effect on malaria transmission through their negative impact on Anopheles
mosquitoes.
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technique [21,22]. However, PCR may still miss cases detected by stool microscopy. Hence, a
combination of real-time PCR with either Baermann or Koga agar plate is suggested to obtain
high sensitivity. However, none of the fecal-based methods validated thus far has reached the
sensitivity of serology.
In order to ease individual patient management and community-based prevalence studies,
there is a need for a stool-based rapid diagnostic test (RDT) for S. stercoralis infection. Such a
tool (i.e., a stool-based antigen detection test) is currently under development within the Euro-
pean Commission (EC)-funded National Infectious Disease Diagnostics (NIDIAG) research
consortium (www.nidiag.org). A prerequisite for the development of such an RDT and to fur-
ther improve existing diagnostic methods is the establishment of a “stool bank” in order to
have access to well-characterized Strongyloides-positive stool samples, cryo-preserved live cul-
tures, and/or frozen antigens. Such a “stool bank” will be facilitated through StrongNet. A bank
of reference sera would be equally important. Serology could also be a useful complement for
prevalence studies in endemic countries, especially if/when fully validated for use on dried
blood spots collected on filter paper.
Screening and Follow-Up of At-Risk Individuals
A targeted screening of individuals at risk of S. stercoralis is justified even in non-endemic
areas by (i) the relatively high prevalence among migrants from endemic countries; (ii) the
potential to diagnose autochthonous infections in some temperate countries that are consid-
ered non-endemic (e.g., parts of southern Europe); (iii) the availability of sensitive screening
methods (e.g., serology and stool-based real-time PCR); (iv) an effective oral treatment with
ivermectin; and, most importantly, (v) the opportunity to avoid the potentially fatal complica-
tions of disseminated strongyloidiasis. Expert consensus guidelines from the EC-funded
research consortium “Coordinating Resources to Assess and Improve Health Status of
Migrants from Latin America” (COHEMI; www.cohemi-project.eu) indicate that immuno-
competent subjects with a high risk of exposure (e.g., immigrants from endemic areas, adopted
children, and expatriates traveling abroad for more than one year) and immunocompromised
individuals or patients who are likely to undergo immunosuppression (e.g., before organ trans-
plantation), even if at low or intermediate risk of exposure to S. stercoralis, should be routinely
screened for S. stercoralis infection with serology plus stool microscopy and/or real-time PCR.
Furthermore, donor-derived transmission of strongyloidiasis during solid organ transplanta-
tion has been documented. Hence, specific guidelines should be employed for systematic
screening of organ donors who might have been at risk of strongyloidiasis [23].
All positive patients should be treated with ivermectin. Furthermore, empiric treatment
with ivermectin of patients at risk of immunosuppression is indicated without testing if past
exposure cannot be excluded and in case of unavailable adequate diagnostic facilities. Post-
treatment follow-up should be performed with the most sensitive technique available.
Treatment of Strongyloidiasis: Access to Ivermectin Is a Bottleneck
Ivermectin is the current treatment of choice for strongyloidiasis [24–27]. Indeed, it is much
more effective than other anthelmintic drugs such as albendazole, as has recently been con-
firmed by a Cochrane systematic review [28]. Ivermectin has improved the treatment of other
human nematode infections and contributed to the successful control of a number of diseases,
such as LF and onchocerciasis, some of which are today on the verge of elimination [29,30].
Half of the 2015 Nobel Prize in Medicine or Physiology was awarded to Drs. William C. Camp-
bell and SatoshiŌmura for the discovery of the nematocidal drug avermectin and its further
development into ivermectin [31–33]. However, the optimal treatment regimen against
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strongyloidiasis remains to be determined. A randomized, multi-center trial is underway to
determine the efficacy of single-dose ivermectin versus four doses for the treatment of uncom-
plicated strongyloidiasis. Participating study centers are located in Italy, Spain, and the United
Kingdom (“StrongTreat 1 to 4;” ClinicalTrials.gov identifier: NCT01570504).
For severe cases in which oral treatment is not feasible, subcutaneous ivermectin (which is
licensed for veterinary use only) has been employed in different treatment centers and warrants
further clinical investigation [34]. In endemic settings, preventive chemotherapy with single-
dose ivermectin in combination with albendazole may considerably impact infection rates with
S. stercoralis and other infectious agents. However, the efficacy of this regimen and its long-
term benefit on S. stercoralismorbidity in spite of possible re-infections remains to be deter-
mined. A major challenge identified by the Basel meeting participants is the highly restricted
access to ivermectin in many LMIC where strongyloidiasis is most prevalent. For instance,
there are countries where the drug is not available outside control programs for the elimination
of LF and onchocerciasis. Moreover, in areas of sub-Saharan Africa where loiasis is endemic,
ivermectin might cause severe adverse events (i.e., encephalopathy) if administered to individ-
uals with loiasis; therefore, community treatment with ivermectin should be cautiously
employed [35]. Additionally, ivermectin is not licensed for human use in most European coun-
tries. Hence, the drug needs to be imported through international pharmacies from, e.g., France
and the Netherlands, where ivermectin is registered.
Public Health Strategies for the Control of Strongyloidiasis in
Endemic Countries
Crucially important agenda items of the meeting were related to updates on the disease burden
in endemic countries, availability of ivermectin, and other control measures. In the remainder
of this piece, a brief update is provided and current knowledge gaps are highlighted.
Prevalence of Strongyloidiasis in Tropical and Subtropical Countries
Several meeting participants reported recent, mainly unpublished results of studies conducted
in endemic areas of three continents: Africa (Ethiopia and Zanzibar), Asia (Cambodia and Peo-
ple’s Republic of China), and South America (Bolivia and Ecuador). Two issues emerged from
these analyses: (i) considerable heterogeneity of prevalence data; and (ii) a large variety of diag-
nostic methods employed.
A survey performed in the northwestern part of Ethiopia in primary school children
(n = 396) reported an S. stercoralis prevalence of 4% with stool microscopy utilizing the forma-
lin-ether concentration technique, 12% with Baermann funnel technique, 13% with PCR, and
21% when considering the different methods combined. Observed co-infection with S. stercor-
alis and hookworm was higher than expected by chance [36].
Recent surveys carried out in Cambodia revealed S. stercoralis infection rates that were con-
siderably higher than previously thought. Indeed, two large-scale, community-based surveys
conducted in two provinces (Takeo and Preah Vihear) involving more than 5,000 individuals
found village infection rates as high as 50%. Furthermore, high infection intensities were found
among infected people, as determined by the number of microscopically observed larvae using
the Baermann method [37,38]. A considerable number of gastrointestinal and dermatologic
symptoms resolved after treatment with ivermectin, thus underscoring the considerable health
impact of chronic strongyloidiasis [39]. A national survey is underway to assess the burden of
S. stercoralis infection throughout Cambodia. It is important to note that in rural parts of Cam-
bodia, access to adequate diagnosis and to ivermectin is lacking.
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Recent data from the People’s Republic of China indicate that S. stercoralismay only occur
in pockets of transmission. A review published in 2013 only reported 330 confirmed cases of S.
stercoralis in the People’s Republic of China from 1973 to 2011 [40]. However, a small commu-
nity-based study conducted in an ethnic minority region in Yunnan province, where hook-
worm and other soil-transmitted helminth infections are rampant, found an S. stercoralis
prevalence as high as 12% based on a combination of different diagnostic approaches [11].
Nonetheless, the epidemiology of S. stercoralis is poorly understood in the People’s Republic of
China, and ivermectin is currently not available for human use.
In the provinces of Cochabamba and Santa Cruz in Bolivia, among adult patients (18
years) at high risk of complications, the serologic and coproparasitologic prevalence was 23.0%
and 7.6%, respectively. Given the known diagnostic performance of the serologic test, the actual
prevalence of strongyloidiasis is estimated around 20% [41]. In Bolivia, direct fecal smear is the
most commonly employed technique in clinical practice. Given the poor awareness on S. ster-
coralis, even among healthcare workers, more sensitive diagnostic techniques are rarely
employed. Since mid-2015, ivermectin is registered in Bolivia. However, access is difficult and
a concerted control strategy remains elusive.
S. stercoralis can even be at high prevalence in marginalized populations in high-income
countries, but data are lacking. Aboriginal Australians living in rural communities may have
prevalences greater than 15% [42,43]. Seroprevalence was 21% among 1,012 Aboriginal people
from Arnhem Land, Northern Territory, decreasing to 6% 12 months after community-wide
ivermectin administration [44]. Information on the epidemiology is very deficient, even in a
high-income country like Australia.
The Role of Preventive Chemotherapy with Ivermectin for the Control of
Strongyloidiasis
A recently published study documented the reduction of S. stercoralis prevalence as an ancillary
benefit of regular mass administration of ivermectin in Esmeraldas province in Ecuador, which
had been carried out in the context of the onchocerciasis elimination program [45]. While the
prevalence of S. stercoralis declined dramatically in the onchocerciasis intervention area, it
remained high in the non-onchocerciasis endemic parts of the province, where no preventive
chemotherapy with ivermectin took place. Similar observations have been made on the two
islands of Zanzibar (Pemba and Unguja), Tanzania, where the Global Program for the Elimina-
tion of Lymphatic Filariasis (GPELF) has employed regular mass treatment with ivermectin
and albendazole over several years (2001–2006). An independent assessment of the prevalence
of S. stercoralis infections on Pemba Island showed a considerable reduction from 41% in 1998
to around 7% in 2013, seven years after the LF elimination program (Box 3).
Moreover, these findings confirm observational data from two cross-sectional surveys car-
ried out in 1994 and 2006/2007 on Unguja Island that found an approximately 80% lower
prevalence of S. stercoralis in the 2006/2007 survey compared to the situation in 1994 [46].
These data provide evidence that S. stercoralis-endemic communities might benefit substan-
tially from regular ivermectin administration within the frame of LF control/elimination
programs.
Collecting available data to demonstrate the impact of large-scale administration of iver-
mectin on the prevalence of S. stercoralis will give more insights on the effectiveness of mass
drug administration and might contribute to include S. stercoralis in the WHO preventive che-
motherapy strategy against soil-transmitted helminthiasis. However, preliminary data analysis
shows that the interpretation of available data is frequently hampered by the paucity of studies
conducted with diagnostic tests with reasonable sensitivity and by inherent differences in the
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design of most studies, which renders comparisons difficult. In a recent community-based
study in eight villages in northern Cambodia, a cohort of 1,269 S. stercoralis patients were fol-
lowed over a 2-year period after treatment with ivermectin (once yearly with a single oral dose
of 200 μg/kg). The intervention proved to be highly beneficial, particularly in combination
with improved sanitation; reinfection rates with S. stercoralismeasured 1 year after the first or
second treatment were 14.4% and 11.0%, respectively [47].
Hence, well-designed community-based cohort studies are needed to confirm the effective-
ness of ivermectin treatment against S. stercoralis beyond the individual patient level. Addition-
ally, a more accurate epidemiologic database would provide more reliable estimates on the true
burden of strongyloidiasis. Taken together, such information will allow for calculating the need
and the demand for ivermectin tablets to control strongyloidiasis (market analysis), which is
an essential prerequisite for any drug donation program that may potentially follow. Such a
market analysis should be done in concert with the scabies research and control community,
which is currently looking for ivermectin donation to reduce the scourge of scabies and other
ectoparasites [50,51]. Beyond strongyloidiasis, LF, and scabies, additional health benefits may
accrue. There is, for instance, evidence that ivermectin-containing blood meals have a negative
impact on the lifespan of Anophelesmosquitoes, thus reducing malaria transmission. It has
been speculated that this strategy might play a role in future malaria control and elimination
efforts [52]. Last, but not least, the combination of ivermectin-albendazole has recently been
proposed as the first-priority combination to be implemented for the treatment, control, and
elimination of soil-transmitted helminthiasis. The underlying rationale for the use of co-
administered drugs is their higher efficacy, not only for S. stercoralis but also for other soil-
transmitted helminths (particularly T. trichiura), than drugs being administered in mono-ther-
apy, which in turn will reduce the risk of anthelmintic resistance against current anthelmintic
drugs [53,54]. Therefore, merging the evidence of the use and demand of ivermectin for the
treatment of strongyloidiasis, scabies, LF, soil-transmitted helminthiasis and, pending further
research, malaria control/elimination might eventually lead to the implementation of a large
ivermectin donation program. More generally speaking, improved availability of ivermectin at
a global scale is warranted. In combination with a market analysis and exploration of potential
public-private mechanisms, this may also stimulate generic producers and pharmaceutical
companies to enter the market and help make ivermectin more widely available. However,
important prerequisites have to be fulfilled; e.g., previous, cost-intensive bioequivalence studies
would need to be performed to achieve pre-qualification by WHO of generic ivermectin
production.
Conclusions
The following recommendations are proposed by StrongNet, the newly instituted international
network on strongyloidiasis:
1. There is a pressing need for an in-depth epidemiologic analysis to further improve the
understanding of the global burden of strongyloidiasis. Research questions on the effects of
larval output on morbidity and the type of gut pathology caused by S. stercoralis need to be
addressed without delay.
2. Sensitive diagnostic tools should continue to be developed, with the ultimate goal of produc-
ing a highly sensitive, stool-based, POC RDT for individual patient diagnosis as well as for
surveillance purposes.
3. Ivermectin should be made available for community-based treatment in S. stercoralis-
endemic communities and for improved patient management, particularly in LMIC.
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004898 September 8, 2016 8 / 12
4. The management of strongyloidiasis in individual patients encountered in daily clinical
practice and a more population-oriented approach to control and eliminate strongyloidiasis
as a public health problem in endemic countries should be tackled as two separate entities.
5. Ivermectin has demonstrated a key role in the control of several NTDs and might poten-
tially be utilized in malaria elimination campaigns. A synergistic collaboration with partners
of the malaria constituency, scabies control, LF, soil-transmitted helminthiasis, and oncho-
cerciasis control and elimination programs should be encouraged, yet care is indicated in
areas where loiasis co-exists.
6. Awareness and political pressure must be enhanced and drug companies engaged to set the
basis of a donation program for the distribution of ivermectin to LMIC and to lower the
cost of the drug for human use. However, solutions that do not solely rely on donation must
also be identified to ensure the sustainability of such programs that are readily tailored to
social-ecological contexts. Appropriate advocacy tools should be used to draw the media’s
attention to the general neglect of strongyloidiasis.
We feel that the time is ripe to push the agenda to facilitate the availability of ivermectin in
LMIC and to add this drug to the available set of interventions for a comprehensive and inte-
grated control of several NTDs. The major goals of the newly established StrongNet are to fill
existing knowledge gaps on epidemiologic research and diagnostics, strengthen evidence, and
provide advocacy for broader ivermectin availability.
Acknowledgments
This manuscript is dedicated to the memory of the late Professor Richard Speare, who tragi-
cally passed away in a motor vehicle accident on June 5, 2016, shortly after having contributed
to this manuscript. Professor Speare was devoted to the cause of eliminating S. stercoralis infec-
tion from the Australian Aboriginal people. He will be sorely missed.
Members of the StrongNet working group:Marco Albonico, Arancha Amor, Andrea
Angheben, Mariella Anselmi, Steven Ault, Beatrice Barda, Alessandro Bartoloni, Sören L.
Becker, Zeno Bisoffi, Maria E. Bottazzi, Emmanuel Bottieau, Richard Bradbury, Norbert
Brattig, Dora Buonfrate, Guido Calleri, Marta Castel, Eric Caumes, Peter L. Chiodini, Enrico
Colli, Philip Cooper, Juan J. de los Santos, Lloyd Einsiedel, Luis Ferrero, Fabio Formenti,
Armelle Forrer, Laurent Gétaz, Federico Gobbi, Spring Gombe-Goetz, Joan Gomez, Eduardo
Gotuzzo, Angel Guevara, Jennifer Keiser, Therese Kearns, Virak Khieu, Stefanie Knopp,
Andrew Kotze, Alejandro Krolewiecki, Patrick Lammie, Ana Luchanez, Pascal Magnussen,
Luis Marcos, Tegwen Marlais, Hanspeter Marti, James McCarthy, Rojelio Mejia, Maria A.
Mena, Pascal Mertens, Michael Miles, Israel Molina, Antonio Montresor, Andreas Mueller,
Jose Muñoz, Sinuon Muth, Andreas Neumayr, Beatrice Nickel, Thomas Nutman, Peter
Odermatt, Annette Olsen, Wendy Page, Francesca Perandin, Maria V. Periago, Khampheng
Phongluxa, Katja Polman, Giovanna Raso, Ana Requena-Méndez, Martha Saboya, Lorenzo
Savioli, Somphou Sayasone, Jorge Seixas, Ann-Marie Sevcsik, Fabian Schär, Harsha Sheorey,
Jennifer Shield, Antoni Soriano Arandes, Richard Speare, Andrew Steer, Peter Steinmann,
Adrian Streit, Teruhisa Tanaka, Jürg Utzinger, Lisette van Lieshout, Jozef Vercruysse, Kris-
tien Verdonck, Leo Visser, Youthanavanh Vonghachack, Christoph Weber, Aya Yajima, and
Lorenzo Zammarchi.
Access to the Strongyloides Sharing Platform is restricted to members. Please contact one of
the administrators of the Platform to receive information on how to join: Andrea Angheben,
Dora Buonfrate, Antonio Montresor, or Zeno Bisoffi.
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004898 September 8, 2016 9 / 12
References
1. Bisoffi Z, Buonfrate D, Montresor A, Requena-Méndez A, Munoz J, Krolewiecki AJ, et al. (2013) Stron-
gyloides stercoralis: a plea for action. PLoS Negl Trop Dis 7:e2214. doi: 10.1371/journal.pntd.0002214
PMID: 23675546
2. Schär F, Trostdorf U, Giardina F, Khieu V, Muth S, Marti H, et al. (2013) Strongyloides stercoralis:
global distribution and risk factors. PLoS Negl Trop Dis 7:e2288. doi: 10.1371/journal.pntd.0002288
PMID: 23875033
3. Olsen A, van Lieshout L, Marti H, Polderman T, Polman K, Steinmann P, et al. (2009) Strongyloidiasis–
the most neglected of the neglected tropical diseases? Trans R Soc Trop Med Hyg 103:967–972. doi:
10.1016/j.trstmh.2009.02.013 PMID: 19328508
4. Utzinger J, Becker SL, Knopp S, Blum J, Neumayr AL, Keiser J, et al. (2012) Neglected tropical dis-
eases: diagnosis, clinical management, treatment and control. Swiss MedWkly 142:w13727. doi: 10.
4414/smw.2012.13727 PMID: 23180107
5. Becker SL, Sieto B, Silué KD, Adjossan L, Koné S, Hatz C, et al. (2011) Diagnosis, clinical features,
and self-reported morbidity of Strongyloides stercoralis and hookworm infection in a co-endemic set-
ting. PLoS Negl Trop Dis 5:e1292. doi: 10.1371/journal.pntd.0001292 PMID: 21886853
6. Buonfrate D, Requena-Méndez A, Angheben A, Munoz J, Gobbi F, Van Den Ende J, et al. (2013)
Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis 13:78. doi: 10.1186/1471-
2334-13-78 PMID: 23394259
7. Montes M, Sawhney C, Barros N (2010) Strongyloides stercoralis: there but not seen. Curr Opin Infect
Dis 23:500–504. doi: 10.1097/QCO.0b013e32833df718 PMID: 20733481
8. Requena-Méndez A, Chiodini P, Bisoffi Z, Buonfrate D, Gotuzzo E, Munoz J (2013) The laboratory
diagnosis and follow up of strongyloidiasis: a systematic review. PLoS Negl Trop Dis 7:e2002. doi: 10.
1371/journal.pntd.0002002 PMID: 23350004
9. Buonfrate D, Formenti F, Perandin F, Bisoffi Z (2015) Novel approaches to the diagnosis of Strongy-
loides stercoralis infection. Clin Microbiol Infect 21:543–552. doi: 10.1016/j.cmi.2015.04.001 PMID:
25887711
10. Khieu V, Schär F, Marti H, Sayasone S, Duong S, Muth S, et al. (2013) Diagnosis, treatment and risk
factors of Strongyloides stercoralis in schoolchildren in Cambodia. PLoS Negl Trop Dis 7:e2035. doi:
10.1371/journal.pntd.0002035 PMID: 23409200
11. Steinmann P, Zhou XN, Du ZW, Jiang JY, Wang LB, Wang XZ, et al. (2007) Occurrence of Strongy-
loides stercoralis in Yunnan province, China, and comparison of diagnostic methods. PLoS Negl Trop
Dis 1:e75. PMID: 17989788
12. Campo Polanco L, Gutiérrez LA, Cardona Arias J (2014) [Diagnosis of Strongyloides stercoralis infec-
tion: meta-analysis on evaluation of conventional parasitological methods (1980–2013)]. Rev Esp
Salud Publica 88:581–600 [in Spanish]. doi: 10.4321/S1135-57272014000500004 PMID: 25327268
13. Knopp S, Mgeni AF, Khamis IS, Steinmann P, Stothard JR, Rollinson D, et al. (2008) Diagnosis of soil-
transmitted helminths in the era of preventive chemotherapy: effect of multiple stool sampling and use
of different diagnostic techniques. PLoS Negl Trop Dis 2:e331. doi: 10.1371/journal.pntd.0000331
PMID: 18982057
14. Buonfrate D, Sequi M, Mejia R, Cimino RO, Krolewiecki AJ, Albonico M, et al. (2015) Accuracy of five
serologic tests for the follow-up of Strongyloides stercoralis infection. PLoS Negl Trop Dis 9:e0003491.
doi: 10.1371/journal.pntd.0003491 PMID: 25668740
15. Sudarshi S, Stumpfle R, Armstrong M, Ellman T, Parton S, Krishnan P, et al. (2003) Clinical presenta-
tion and diagnostic sensitivity of laboratory tests for Strongyloides stercoralis in travellers compared
with immigrants in a non-endemic country. Trop Med Int Health 8:728–732. PMID: 12869094
16. Gétaz L, Zamora P, Castro R, Kramer M, Lisarazu S, Chappuis F (2015) Sensitivity of Strongyloides
IgG antibody detection by ELISA among immunocompromised patients. Oral presentation at the 9th
European Congress on Tropical Medicine and International Health; September 2015, Basel,
Switzerland.
17. Sousa-Figueiredo JC, Day M, Betson M, Rowell C, Wamboko A, Arinaitwe M, et al. (2011) Field survey
for strongyloidiasis in eastern Uganda with observations on efficacy of preventive chemotherapy and
co-occurrence of soil-transmitted helminthiasis/intestinal schistosomiasis. J Helminthol 85:325–333.
doi: 10.1017/S0022149X10000623 PMID: 20961473
18. Bisoffi Z, Buonfrate D, Sequi M, Mejia R, Cimino RO, Krolewiecki AJ, et al. (2014) Diagnostic accuracy
of five serologic tests for Strongyloides stercoralis infection. PLoS Negl Trop Dis 8:e2640. doi: 10.
1371/journal.pntd.0002640 PMID: 24427320
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004898 September 8, 2016 10 / 12
19. Verweij JJ, Canales M, Polman K, Ziem J, Brienen EA, Polderman AM, et al. (2009) Molecular diagno-
sis of Strongyloides stercoralis in faecal samples using real-time PCR. Trans R Soc Trop Med Hyg
103:342–346. doi: 10.1016/j.trstmh.2008.12.001 PMID: 19195671
20. Meurs L, Brienen E, MbowM, Ochola EA, Mboup S, Karanja DM, et al. (2015) Is PCR the next refer-
ence standard for the diagnosis of Schistosoma in stool? A comparison with microscopy in Senegal
and Kenya. PLoS Negl Trop Dis 9:e0003959. doi: 10.1371/journal.pntd.0003959 PMID: 26217948
21. Becker SL, Piraisoody N, Kramme S, Marti H, Silué KD, Panning M, et al. (2015) Real-time PCR for
detection of Strongyloides stercoralis in human stool samples from Côte d'Ivoire: diagnostic accuracy,
inter-laboratory comparison and patterns of hookworm co-infection. Acta Trop 150:210–217. doi: 10.
1016/j.actatropica.2015.07.019 PMID: 26215130
22. Saugar JM, Merino FJ, Martin-Rabadan P, Fernandez-Soto P, Ortega S, Garate T, et al. (2015) Appli-
cation of real-time PCR for the detection of Strongyloides spp. in clinical samples in a reference center
in Spain. Acta Trop 142:20–25. doi: 10.1016/j.actatropica.2014.10.020 PMID: 25447829
23. Abanyie FA, Gray EB, Delli Carpini KW, Yanofsky A, McAuliffe I, Rana M, et al. (2015) Donor-derived
Strongyloides stercoralis infection in solid organ transplant recipients in the United States, 2009–2013.
Am J Transplant 15:1369–1375. doi: 10.1111/ajt.13137 PMID: 25703251
24. Marti H, Haji HJ, Savioli L, Chwaya HM, Mgeni AF, Ameir JS, et al. (1996) A comparative trial of a sin-
gle-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and
other soil-transmitted helminth infections in children. Am J Trop Med Hyg 55:477–481. PMID: 8940976
25. Bisoffi Z, Buonfrate D, Angheben A, Boscolo M, Anselmi M, Marocco S, et al. (2011) Randomized clini-
cal trial on ivermectin versus thiabendazole for the treatment of strongyloidiasis. PLoS Negl Trop Dis 5:
e1254. doi: 10.1371/journal.pntd.0001254 PMID: 21814588
26. Suputtamongkol Y, Premasathian N, Bhumimuang K, Waywa D, Nilganuwong S, Karuphong E, et al.
(2011) Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albenda-
zole for chronic strongyloidiasis. PLoS Negl Trop Dis 5:e1044. doi: 10.1371/journal.pntd.0001044
PMID: 21572981
27. Luvira V, Watthanakulpanich D, Pittisuttithum P (2014) Management of Strongyloides stercoralis: a
puzzling parasite. Int Health 6:273–281. doi: 10.1093/inthealth/ihu058 PMID: 25173343
28. Henriquez-Camacho C, Gotuzzo E, Echevarria J, White AC Jr., Terashima A, Samalvides F, et al.
(2016) Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection.
Cochrane Database Syst Rev 1:CD007745. doi: 10.1002/14651858.CD007745.pub3 PMID:
26778150
29. Taylor MJ, Hoerauf A, Bockarie M (2010) Lymphatic filariasis and onchocerciasis. Lancet 376:1175–
1185. doi: 10.1016/S0140-6736(10)60586-7 PMID: 20739055
30. Cupp EW, Sauerbrey M, Richards F (2011) Elimination of human onchocerciasis: history of progress
and current feasibility using ivermectin (Mectizan) monotherapy. Acta Trop 120 Suppl 1:S100–108.
doi: 10.1016/j.actatropica.2010.08.009 PMID: 20801094
31. Dlugónska H (2015) The Nobel Prize 2015 in physiology or medicine for highly effective antiparasitic
drugs. Ann Parasitol 61:299–301. doi: 10.17420/ap6104.23 PMID: 26878630
32. Molyneux DH, Ward SA (2015) Reflections on the Nobel Prize for Medicine 2015 –the public health leg-
acy and impact of avermectin and artemisinin. Trends Parasitol 31:605–607. doi: 10.1016/j.pt.2015.10.
008 PMID: 26552892
33. Tambo E, Khater EI, Chen JH, Bergquist R, Zhou XN (2015) Nobel prize for the artemisinin and iver-
mectin discoveries: a great boost towards elimination of the global infectious diseases of poverty. Infect
Dis Poverty 4:58. doi: 10.1186/s40249-015-0091-8 PMID: 26708575
34. Barrett J, Broderick C, Soulsby H, Wade P, NewsholmeW (2016) Subcutaneous ivermectin use in the
treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the litera-
ture. J Antimicrob Chemother 71:220–225. doi: 10.1093/jac/dkv315 PMID: 26462990
35. Twum-Danso NA (2003) Loa loa encephalopathy temporally related to ivermectin administration
reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future.
Filaria J 2 Suppl 1:S7. PMID: 14975064
36. Amor A, Anegagrie M, Rodriguez E, Saugar JM, Arroyo A, López-Quintana B, et al. (2015) High preva-
lence of Strongyloides stercoralis in rural area of Amhara region, north-western Ethiopia, by using a
combination of three different techniques. Poster presentation at the 9th European Congress on Tropi-
cal Medicine and International Health; September 2015, Basel, Switzerland.
37. Khieu V, Schär F, Forrer A, Hattendorf J, Marti H, Duong S, et al. (2014) High prevalence and spatial
distribution of Strongyloides stercoralis in rural Cambodia. PLoS Negl Trop Dis 8:e2854. doi: 10.1371/
journal.pntd.0002854 PMID: 24921627
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004898 September 8, 2016 11 / 12
38. Khieu V, Schär F, Marti H, Bless PJ, Char MC, Muth S, et al. (2014) Prevalence and risk factors of
Strongyloides stercoralis in Takeo province, Cambodia. Parasit Vectors 7:221. doi: 10.1186/1756-
3305-7-221 PMID: 24886763
39. Khieu V, Srey S, Schär F, Muth S, Marti H, Odermatt P (2013) Strongyloides stercoralis is a cause of
abdominal pain, diarrhea and urticaria in rural Cambodia. BMCRes Notes 6:200. doi: 10.1186/1756-
0500-6-200 PMID: 23688049
40. Wang C, Xu J, Zhou X, Li J, Yan G, James AA, et al. (2013) Strongyloidiasis: an emerging infectious
disease in China. Am J Trop Med Hyg 88:420–425. doi: 10.4269/ajtmh.12-0596 PMID: 23468357
41. Gétaz L, Castro R, Perneger T, Zamora P, Kramer M, Lisarazu S, et al. (2015) Prevalence and risk fac-
tors for Strongyloides stercoralis infection among patients at high risk of complications in Bolivia. Poster
presentation at the 9th European Congress on Tropical Medicine and International Health; September
2015, Basel, Switzerland.
42. Johnston FH, Morris PS, Speare R, McCarthy J, Currie B, Ewald D, et al. (2005) Strongyloidiasis: a
review of the evidence for Australian practitioners. Aust J Rural Health 13:247–254. PMID: 16048468
43. Mounsey K, Kearns T, Rampton M, Llewellyn S, King M, Holt D, et al. (2014) Use of dried blood spots to
define antibody response to the Strongyloides stercoralis recombinant antigen NIE. Acta Trop 138:78–
82. doi: 10.1016/j.actatropica.2014.07.007 PMID: 25051188
44. Kearns TK (2013) Scabies and strongyloidiasis prevalence before and after a mass drug administration
in a remote Aboriginal community in the Northern Territory. PhD thesis, Charles Darwin University,
Australia.
45. Anselmi M, Buonfrate D, Guevara Espinoza A, Prandi R, Marquez M, Gobbo M, et al. (2015) Mass
administration of ivermectin for the elimination of onchocerciasis significantly reduced and maintained
low the prevalence of Strongyloides stercoralis in Esmeraldas, Ecuador. PLoS Negl Trop Dis 9:
e0004150. doi: 10.1371/journal.pntd.0004150 PMID: 26540412
46. Knopp S, Mohammed KA, Rollinson D, Stothard JR, Khamis IS, Utzinger J, et al. (2009) Changing pat-
terns of soil-transmitted helminthiases in Zanzibar in the context of national helminth control programs.
Am J Trop Med Hyg 81:1071–1078. doi: 10.4269/ajtmh.2009.09-0377 PMID: 19996439
47. Forrer A, Khieu V, Schindler C, Schär F, Marti H, Char MC, et al. (2016) Ivermectin Treatment and Sani-
tation Effectively Reduce Strongyloides stercoralis Infection Risk in Rural Communities in Cambodia.
PLoS Negl Trop Dis 10(8): e0004909. doi: 10.1371/journal.pntd.0004909
48. Knopp S, Mohammed KA, Speich B, Hattendorf J, Khamis IS, Khamis AN, et al. (2010) Albendazole
and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura: a
randomized controlled trial. Clin Infect Dis 51:1420–1428. doi: 10.1086/657310 PMID: 21062129
49. Mohammed KA, Deb RM, Stanton MC, Molyneux DH (2012) Soil-transmitted helminths and scabies in
Zanzibar, Tanzania following mass drug administration for lymphatic filariasis–a rapid assessment
methodology to assess impact. Parasit Vectors 5:299. doi: 10.1186/1756-3305-5-299 PMID:
23259465
50. Romani L, Whitfeld MJ, Koroivueta J, KamaM,Wand H, Tikoduadua L, et al. (2015) Mass drug admin-
istration for scabies control in a population with endemic disease. N Engl J Med 373:2305–2313. doi:
10.1056/NEJMoa1500987 PMID: 26650152
51. Romani L, Steer AC, Whitfeld MJ, Kaldor JM (2015) Prevalence of scabies and impetigo worldwide: a
systematic review. Lancet Infect Dis 15:960–967. doi: 10.1016/S1473-3099(15)00132-2 PMID:
26088526
52. Chaccour CJ, Rabinovich NR, Slater H, Canavati SE, Bousema T, Lacerda M, et al. (2015) Establish-
ment of the Ivermectin Research for Malaria Elimination Network: updating the research agenda. Malar
J 14:243. doi: 10.1186/s12936-015-0691-6 PMID: 26068560
53. Speich B, Ame SM, Ali SM, Alles R, Huwyler J, Hattendorf J, et al. (2014) Oxantel pamoate-albenda-
zole for Trichuris trichiura infection. N Engl J Med 370:610–620. doi: 10.1056/NEJMoa1301956 PMID:
24521107
54. Speich B, Moser W, Ali SM, Ame SM, Albonico M, Hattendorf J, et al. (2016) Efficacy and reinfection
with soil-transmitted helminths 18-weeks post-treatment with albendazole-ivermectin, albendazole-
mebendazole, albendazole-oxantel pamoate and mebendazole. Parasit Vectors 9:123. doi: 10.1186/
s13071-016-1406-8 PMID: 26935065
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004898 September 8, 2016 12 / 12
